An alternate conformation of HCV E2 neutralizing face as an additional vaccine target

Netanel Tzarum, Erick Giang, Rameshwar U. Kadam, Fang Chen, Kenna Nagy, Elias H. Augestad, Rodrigo Velázquez-Moctezuma, Zhen Yong Keck, Yuanzi Hua, Robyn L. Stanfield, Marlene Dreux, Jannick Prentoe, Steven K.H. Foung, Jens Bukh, Ian A. Wilson*, Mansun Law*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


To achieve global elimination of hepatitis C virus (HCV), an effective cross-genotype vaccine is needed. The HCV envelope glycoprotein E2 is the main target for neutralizing antibodies (nAbs), which aid in HCV clearance and protection. E2 is structurally flexible and functions in engaging host receptors. Many nAbs bind to the “neutralizing face” on E2, including several broadly nAbs encoded by the VH1-69 germline gene family that bind to a similar conformation (A) of this face. Here, a previously unknown conformation (B) of the neutralizing face is revealed in crystal structures of two of four additional E2-VH1-69 nAb complexes. In this conformation, the E2 front-layer region is displaced upon antibody binding, exposing residues in the back layer for direct antibody interaction. This E2 B structure may represent another conformational state in the viral entry process that is susceptible to antibody neutralization and thus provide a new target for rational vaccine development.

Original languageAmerican English
Article numberabb5642
JournalScience advances
Issue number30
StatePublished - Jul 2020

Bibliographical note

Publisher Copyright:
© 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).


Dive into the research topics of 'An alternate conformation of HCV E2 neutralizing face as an additional vaccine target'. Together they form a unique fingerprint.

Cite this